CatalystWireBeta

UK small-cap RNS · 29 Sep 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.

  1. 17:43
    Update on Liberation Bioindustries
    Liberation's strategic review found no acceptable offers, expected funding was not received and a c.$25m gap remains. The Richmond plant misses its Q4 2026 completion target, and funding is only targeted for H1 2027.
    Project milestones outlook negative, lowered −8.6% on the day
    Moved: Liberation Bioindustries fermentation plant build: Nearing completion; first tranche closed → Funding gap; completion slipped beyond Q4 2026
  2. 16:20
  3. 15:50
  4. 15:00
    Director/PDMR Shareholding Director dealing
  5. 14:08
    Half-year Results Results
    Wider loss of £1.440m, driven by an £849k share-based charge, and cash of only £0.051m at 30 June. Azteca has since reached hot commissioning, and a £2.25m raise followed the period end.
    Project milestones outlook mixed +0.0% on the day
    Moved: Azteca Plant restart: Hot commissioning underway; Operating Licence pending → Hot commissioning underway; licence pending · Placing and retail offer: Proceeds use now stated → Placing admitted; retail admission pending
  6. 13:48
    Publication of Scheme Document Announcement
    Scheme Document published for the recommended 250p final cash offer; the board unanimously backs it, and shareholder meetings on 30 Oct 2026 move the deal toward completion in Q4 2026 or Q1 2027.
    Takeover target −0.2% on the day
  7. 12:30
    2026 Annual Accounts Timetable
    Late 2026 accounts breach AIM Rule 19, so the shares are suspended from 1 October 2026. This repeats the earlier suspension and hampers the cash shell's six-month reverse takeover search.
    Legal & regulatory outlook negativefirst since Oct 2023 +9.5% on the day
    Moved: new: AIM suspension over late accounts – Suspension from 1 October 2026
  8. 11:40
  9. 10:34
    Vesuvius VSVS £1,093m
    Statement re Possible Offer Offer
    RHIM says it is in advanced talks with the Vesuvius board on a possible recommended cash-and-share offer at 549p, a c.47% premium. The board is no longer simply rejecting.
    Takeover target £0.0m · 0% of mcapfirst since Oct 2023 +24.7% on the day
    Moved: Offer for the company: Possible offer; board evaluating latest proposal → Offer period; advanced talks, no firm offer
  10. 09:09
    Replacement - SPA for Kamiesberg Mineral Project
    The SPA is signed, but nothing has completed. The US$33m reverse takeover still needs funding, a prospectus and shareholder approval. The target is pre-revenue and loss-making, and funders are only 'at varying stages'.
    Large acquisition / reverse takeover outlook positive +1.9% on the day
    Moved: Reverse takeover in mining: SPA signed; prospectus, funding and approvals pending → SPA executed; funding, prospectus and approvals pending
  11. 07:40
    WRAP Retail Offer Fundraise
    SEED Innovations Limited (AIM: SEED), the investing company focused on early-stage physical AI and robotics, is pleased to announce a retail offer via the Winterflood Retail Access Platform (“WRAP”) to raise approximately £150,000 (the “Retail Offer”) through …
    Dilutive fundraise 3% of mcap +0.0% on the day
  12. 07:00
    Director/PDMR Shareholding Director dealing
  13. 07:00
  14. 07:00
  15. 07:00
    Final Results and CEO Succession Results
    Continuing revenue grew 16.0% proforma on volume and adjusted EBITDA rose to £7.9m, but EBITDA margin fell to 15.7% and continuing diluted EPS was a 2.98p loss.
    Capital return outlook positivefirst in 1 year −5.4% on the day
    Moved: new: CEO succession – Announced; handover on 31 December 2026 · Share buyback programme: Extended after 31 July expiry; £6.0m spent → Extended programme run to 28 September; 10.6m shares bought · Earnings-enhancing M&A pursuit: FemiClear/CUROXEN done; more deals sought → FemiClear/CUROXEN done; others under exploration
  16. 07:00
    Trading Update,Contract & Working Capital Facility Trading update
    Near-term H2 volumes slower than anticipated, with some revenue pushed into FY27 by Middle East deferrals and a UK supplier outage. H2 EBITDA only similar to H2 FY25, trimming the 'material improvement' guided in June.
    Upgrade / downgrade cycle below expectationsoutlook mixed, loweredfirst since Oct 2023 −6.1% on the day
    Moved: Record order book delivery: New c.€1m award; delivery due in 2026 → €6m extension awarded, FID-dependent; FY26 revenue partly slips · Middle East disruption to projects: Disruption ongoing, bottlenecks easing → Prolonged; now deferring Q4 work and awards
  17. 07:00
    Half-year Results Results
    Loyalty membership is growing, with Burrito Society above 385,000 members and member revenue up about 50%. Growing delivery and in-store demand supports the UK sales momentum.
    Balance-sheet stress / refinancing ahead of expectationsoutlook positivefirst in 8 months +0.0% on the day
    Moved: French store conversions to Tortilla: Three sites closed; disposal talks active → Seven converted; five Fresh Burritos closed; one left · Leadership reset and strategic priorities: Accounts published; new three-year plan → Ten Key Objectives progressing; plan due early Q4 · Covenant waivers after French restatement: Accounts published; suspension lift sought → Net debt rising; suspension and covenant status not updated
  18. 07:00
    Half-year Results Results
    GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer announces its unaudited interim results for the six months ended 30 June 2026.
    Upgrade / downgrade cycle first in 12 months −20.0% on the day
  19. 07:00
    Final Results Results
    Year-end backlog was £83.5m, below last year's £93.4m. The record award then lifted it to about £115m by 31 July, giving revenue visibility into FY27 after the weak H1 bookings.
    Upgrade / downgrade cycle £58.9m · 81% of mcapoutlook positive −2.0% on the day
    Moved: Contracted Backlog rebuild: Backlog rebuilt to c.£115m → Backlog about £115m at 31 July 2026
  20. 07:00
    Half-year Results Results
    Interim results show net assets up to £87m after the March raise and a wider loss of £4.6m. The 4 Sep fatal incident and development suspension overshadow the funded construction progress.
    Project milestones outlook mixed −3.5% on the day
    Moved: Tulu Kapi project financing and construction: Suspended; development plan and schedule under review → Suspended; stakeholders support careful resumption
  21. 07:00
    Interim Results and Board Change Results
    H1 revenue rose 29.1% and profit before tax 70.1% after a weak 2025, and full-year results are expected in line with market expectations, so the recovery is on track.
    Turnaround plan with targets in lineoutlook positive3 leadership changes in 3 months – usually less than 1 +0.0% on the day
    Moved: 2026 earnings recovery: Order book building; 2027 in line with expectations → H1 profit up 70%; record order book · Yate closure, Barnsley consolidation: Yate closed; steel operations consolidated at Barnsley → Consolidation done; Yate vacated, marketed for sale · new: CEO succession – Successor named; handover planned
  22. 07:00
    Half-year Results Results
    Unaudited Interim Results for the six months ended 30 June 2026
    Upgrade / downgrade cycle ahead of expectationsfirst in 1 year +0.0% on the day
  23. 07:00
    Fundraising & Director Holdings Fundraise
    Fundraising to Advance Physical AI & Robotics Strategy
    Dilutive fundraise +0.0% on the day
  24. 07:00
    Half-year Results Results
    H1 revenue and adjusted EBITDA fell year on year as Research normalised, and full-year guidance rests on a stronger H2 from NIOX PRO rollout, Japan pricing and the deferred Clinical demand.
    Capital return £12.5m · 4% of mcapin lineoutlook positivefirst in 6 months +3.7% on the day
    Moved: NIOX PRO device rollout: CE Mark and MHRA obtained; US/Japan pending → CE/MHRA rollout begun; US, Japan submissions progressing · US direct sales transition: US field sales organisation fully deployed → Field sales team deployed March; no material 2026 revenue impact · NIOX MyNO home-use device: Development underway → Development continuing
  25. 07:00
    Post Year-End Trading Update Trading update
    Guidance moves from 'in line' at the May interims to FY2026 'ahead of market expectations' (consensus £37.2m adjusted operating profit). Stronger collectables demand and a record World Cup contribution drove the beat.
    Transformational contract / build-out ahead of expectationsoutlook positive, raised +4.4% on the day
    Moved: News UK national distribution network expansion: Four national contracts signed; footprint still to be built → Build programme started; first go-live July 2027
  26. 07:00
    Half-year Results Results
    Interim profit before tax of £6.248m (H1 2025: £0.151m) follows the Zenit part-sale, while cash of c.£17.3m (£5.4m at start of year) funds the Dokwe DFS without new equity.
    Project milestones outlook positive −5.3% on the day
    Moved: Dokwe RC drilling campaign: DFS under way; Executive Chairman appointed → DFS under way; funded · Xinhai strategic investment in Dokwe: Metallurgical sampling done; testwork pending → Drilling done; testwork pending
  27. 07:00
    Capital Markets Day sets out growth drivers underpinning medium-term ambition
    The Capital Markets Day sets out unit growth targets and KPIs under the reorganised four-unit structure, but the group 5–8% net revenue growth ambition and £30m a year buyback are unchanged, so nothing new for the group.
    Turnaround plan with targets outlook positivefirst since Oct 2023 +5.0% on the day
    Moved: Keep net debt/EBITDA at 1.2x-1.5x through FY28: pending → on_track – Leverage is stated to be within the Board's target range. · Four-unit reorganisation and cost review: Reorganisation largely complete; early positive signs → Capital Markets Day held; unit targets and KPIs set · Capital Markets Day strategy update: Planned for September 2026, after June results → Held on 29 September 2026 (closed)

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note